Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study

Fernando J Martinez,Klaus F Rabe,Gary T Ferguson,Jadwiga A Wedzicha,Dave Singh,Chen Wang,Kimberly Rossman,Earl St Rose,Roopa Trivedi,Shaila Ballal,Patrick Darken,Magnus Aurivillius,Colin Reisner,Paul Dorinsky,Fernando J. Martinez,Klaus F. Rabe,Gary T. Ferguson,Jadwiga A. Wedzicha,Earl St. Rose

DOI: https://doi.org/10.1164/rccm.202006-2618oc

IF: 24.7

2021-03-01

American Journal of Respiratory and Critical Care Medicine

Abstract:<b>Rationale:</b> In the phase III, 52-week ETHOS (Efficacy and Safety of Triple Therapy in Obstructive Lung Disease) trial in chronic obstructive pulmonary disease (COPD) (NCT02465567), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF) significantly reduced all-cause mortality compared with glycopyrrolate/formoterol fumarate (GFF). However, 384 of 8,509 patients were missing vital status at Week 52 in the original analyses.<b>Objectives:</b> To assess the robustness of the ETHOS mortality findings after additional data retrieval for patients missing Week 52 vital status in the original analyses.<b>Methods:</b> Patients with moderate to very severe COPD and prior history of exacerbation received twice-daily dosing with 320/18/9.6 μg of BGF (BGF 320), 160/18/9.6 μg of BGF (BGF 160), 18/9.6 μg of GFF, or 320/9.6 μg of budesonide/formoterol fumarate (BFF) (all delivered via a single metered-dose Aerosphere inhaler). Time to death (all-cause) was a prespecified secondary endpoint.<b>Measurements and Main Results:</b> In the final retrieved dataset, which included Week 52 vital status for 99.6% of the intent-to-treat population, risk of death with BGF 320 was significantly lower than GFF (hazard ratio, 0.51; 95% confidence interval, 0.33-0.80; unadjusted <i>P</i> = 0.0035). There were no significant differences in mortality when comparing BGF 320 with BFF (hazard ratio, 0.72; 95% confidence interval, 0.44-1.16; <i>P</i> = 0.1721), nor were significant differences observed when comparing BGF 160 against either dual comparator. Results were similar when the first 30, 60, or 90 days of treatment were excluded from the analysis. Deaths from cardiovascular causes occurred in 0.5%, 0.8%, 1.4%, and 0.5% of patients in the BGF 320, BGF 160, GFF, and BFF groups, respectively.<b>Conclusions:</b> Using final retrieved vital status data, triple therapy with BGF 320 reduced the risk of death compared with GFF, but was not shown to significantly reduce the risk of death compared with BFF, in patients with COPD. Triple therapy containing a lower dose of inhaled corticosteroid (BGF 160) was not shown to significantly reduce the risk of death compared with the dual therapy comparators.

respiratory system,critical care medicine

What problem does this paper attempt to address?

The problem that this paper attempts to solve is whether the use of triple therapy (budesonide/glycopyrronium/formoterol, abbreviated as BGF) can reduce all - cause mortality in patients with chronic obstructive pulmonary disease (COPD), especially when compared with double therapy (glycopyrronium/formoterol, abbreviated as GFF). Specifically, the study aims to evaluate:

1. Whether **BGF 320/18/9.6 μg** can significantly reduce all - cause mortality compared to **GFF 18/9.6 μg**.
2. Whether **BGF 320/18/9.6 μg** can significantly reduce all - cause mortality compared to **budesonide/formoterol (BFF 320/9.6 μg)**.
3. Whether **BGF 160/18/9.6 μg** can significantly reduce all - cause mortality compared to **GFF 18/9.6 μg** and **BFF 320/9.6 μg**.

In addition, the study also explores the following issues:

- **Data integrity**: Verify the robustness of the original analysis results by supplementarily collecting the missing 52 - week vital status data.
- **ICS withdrawal effect**: Evaluate the impact of acute ICS withdrawal on mortality.
- **Subgroup analysis**: Conduct subgroup analysis according to patients' baseline characteristics (such as previous exacerbation history, percentage of predicted FEV1, blood eosinophil count, etc.) to determine which patient groups may benefit the most from triple therapy.
- **Relationship between COPD exacerbation and death**: Analyze the relationship between COPD exacerbation and death, especially the time interval from exacerbation to death.

Through these analyses, the study aims to comprehensively evaluate the safety and effectiveness of triple therapy in COPD patients, especially its role in reducing all - cause mortality.